KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Chemed (CHE) Asset Writedowns and Impairment (2016 - 2020)

Chemed (CHE) has 11 years of Asset Writedowns and Impairment data on record, last reported at -$443000.0 in Q4 2020.

  • For Q4 2020, Asset Writedowns and Impairment changed N/A year-over-year to -$443000.0; the TTM value through Dec 2020 reached $657000.0, changed N/A, while the annual FY2020 figure was $657000.0, N/A changed from the prior year.
  • Asset Writedowns and Impairment reached -$443000.0 in Q4 2020 per CHE's latest filing, down from $229000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $4.7 million in Q3 2017 and bottomed at -$443000.0 in Q4 2020.
  • Average Asset Writedowns and Impairment over 4 years is $2.8 million, with a median of $4.0 million recorded in 2017.
  • Peak YoY movement for Asset Writedowns and Impairment: surged 33.05% in 2016, then plummeted 87.96% in 2020.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at $4.2 million in 2016, then rose by 3.96% to $4.4 million in 2017, then crashed by 47.16% to $2.3 million in 2019, then crashed by 119.26% to -$443000.0 in 2020.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were -$443000.0 in Q4 2020, $229000.0 in Q3 2020, and $277000.0 in Q2 2020.